Granada and Madrid, Spain and Philadelphia, PA, U.S., September 28, 2010 – Integromics, a market leader in IT solutions provision for life sciences in the areas of genomics and proteomics, today announces that it has selected Dr. Michael J. McManus as President & CEO. Dr. McManus will lead the company’s efforts to expand in the world market, with a particular focus on proteomics and on further developing Integromics’ activity in the U.S. and Asian markets.
Jose Maria Carazo, principal founder, Integromics said, “We performed an extensive search to identify and secure someone with Michael’s background, which is unique in the life science informatics business. Integromics needs someone who understands both the software and scientific markets in the U.S., Europe and Asia and the science. By combining his deep scientific expertise and broad international business experience, Michael can lead Integromics to a new level of growth in the life sciences informatics market.”
“Integromics has an impressive team that has enabled the company to produce and market world-class products,” said Dr. McManus. “The company combines well-established and well-regarded products, such as StatMiner and IBD, with a growing revenue base and solid partnerships. In addition, the team has been working diligently on its latest product; an analysis suite for Next Generation Sequencing data. A pre-release version of this NGS product was used to perform the data analysis in a recent Nature paper. I am delighted to join such a highly dedicated team of professionals, and I plan to expand the company’s product offerings from its roots in micro-array analysis and qPCR analysis to proteomics and Next Generation Sequencing (NGS).”
Dr. McManus, 52, has over 25 years of scientific software and business experience, including operational management, business development, strategic planning, research and development, product marketing and product management expertise. His scientific background spans chemistry (including synthetic organic, computational, cheminformatics, and polymer chemistry sub-disciplines), bioinformatics, data mining and visualization. Dr. McManus received his Ph.D. in synthetic organic chemistry from the Massachusetts Institute of Technology. He received his B.S. in chemistry, summa cum laude, from the University of Massachusetts, Amherst.
Prior to joining Integromics, Dr. McManus led GenomeQuest’s corporate marketing, strategic alliances, product marketing and product development efforts. Before joining GenomeQuest, Dr. McManus served as Vice President of Business Development for the BioSciences Group of Fujitsu Computer Systems, where he set up and initiated the Group’s U.S. operations and as Executive VP and COO of AnVil Informatics, Inc. Prior to AnVil, he served as Vice President of Marketing and Business Development at CambridgeSoft Corporation.
About Integromics(R) S.L
INTEGROMICS, S.L. provides IT solutions for Life Sciences in the areas of Genomics and Proteomics. In the post-genomic era, Integromics S.L. offers state-of-the-art products, services and training in two strategic areas: data management/integration and intelligent data analysis. The company has developed a network of collaborators both in industry and academia to provide complete technological solutions that will help our clients to achieve their goals. Integromics(R) S.L. was founded in 2002 and is based in Granada, Spain, with offices in Madrid, Spain. Integromics, Inc., a wholly owned subsidiary that was established in 2007 is based Philadelphia, PA. For more information, visit http://www.integromics.com
Lynne Chapman ANDREW LLOYD & ASSOCIATES http://www.ala.com lynne@ala.com
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION
